Aaron Kesselheim
@akesselheim
Followers
5K
Following
437
Statuses
831
Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital
Boston
Joined February 2009
@ASLMENews @JLME_ASLME Congrats to contest winner @DrMarkLythgoe for a remarkably precisely accurate submission! Mark, I will email to process your prize. Thanks to everyone else for playing -- maybe next time!
1
1
4
Happy to have the opportunity to hype this huge new piece that happened to hit on this holiday: led by @bnrome, a viewpoint on issues relating to the emergence (hooray!) of new biosimilar Humira:
0
4
14
@statesdj @JAMAInternalMed @charliecwlee @bnrome @PORTAL_Research Thanks! If you email me I’ll get you a copy
0
0
0
RT @JAMAInternalMed: Introduction of a citrate-free version of adalimumab in 2018 avoided Medicaid's inflationary rebates and led to >$4B e…
0
5
0
RT @JAMAHealthForum: New cross-sectional study finds that more than half of #AcceleratedApproval confirmatory trials are completed after th…
0
15
0
Important session next week on racial discrimination and pulse oximetry in the @PORTAL_Research and Center for Bioethics health policy and bioethics consortium! Register please!
0
2
6
RT @medpagetoday: Despite new penalties via the #InflationReductionAct, drug companies raised prices for nearly 1k drugs in January. Is Con…
0
7
0
RT @JAMAHealthForum: Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, accor…
0
5
0
RT @bnrome: Is It Business as Usual for the Drug Industry? In @medpagetoday, Alex Egilman, @akesselheim, and I explain why drug companies…
0
7
0
Watch @PORTAL_Research @AmeetSarpatwari speak at today's @SenateHELP hearing on COVID vaccine pricing -- and check out our @BostonGlobe op-ed from @DrHussainL on the public funding critical to its development:
0
4
18
New entry in the @NEJM Fundamentals of Health Law Series! Consolidation and competition in the health care sector -- and implications for patients and pricing; from Jaime King. Collect them all!:
Next in our @NEJM Fundamentals of Health Law series: a focus on fraud/abuse and COI rules with Prof Zack Buck from Univ of Tennessee:
0
1
5
RT @GlobeOpinion: Policy makers have several options to maximize benefits from public investments and improve returns for the entire global…
0
3
0
RT @NEJM: The FDA has long conducted its oversight of prescription drugs and other products with deference from courts. But mounting judici…
0
11
0
RT @wbfeldman: Great article from @ZacharyBrennan
@endpts today covering our new work @Health_Affairs on inhaler patents and litigation. W…
0
7
0
RT @Harvard: According to new findings, some of the most heavily advertised drugs are often no better at treating a disease than lesser kno…
0
12
0
RT @bnrome: Interesting point by @sean_r_dickson… maybe the new Medicaid rebate rules were one of the factors driving Lilly to lower list p…
0
4
0
Next in our @NEJM Fundamentals of Health Law series: a focus on fraud/abuse and COI rules with Prof Zack Buck from Univ of Tennessee:
Our @NEJM Fundamentals of Health Law series continues with an overview of regulation and reproductive medicine from @ProfessorMutch:
0
1
4
@Eddie_Cliff @PORTAL_Research @DrHussainL @AlexChaitoff @DavalJoseph @AdamR_UBC @frazer_tessema @oncology_bg @darioT_ Looking good, team!
0
0
4